Literature DB >> 32124495

Increased risk of psychiatric disorders in adult patients with vitiligo: A nationwide, population-based cohort study in Taiwan.

Chih-Yu Chen1, Wei-Ming Wang1,2, Chi-Hsiang Chung3,4, Chang-Huei Tsao5,6, Wu-Chien Chien3,5,7, Chih-Tsung Hung1,2.   

Abstract

Vitiligo is an autoimmune skin disease that has a major impact on the quality of life of patients. However, a nationwide study of the association between vitiligo and the incidence of inclusive psychiatric diseases has not been conducted in the Asian population. Therefore, this study aimed to analyze the association between vitiligo and the risk of psychiatric disorders using a nationwide database in Taiwan. Data were collected from the National Health Insurance Research Database of Taiwan from 2000 to 2013. In total, 1432 subjects with vitiligo and 5728 age-, sex- and index year-matched controls were enrolled in this study. Patients with vitiligo tend to have more coexisting psychiatric disorders than healthy individuals, regardless of their sex, age group and facility level of care. After adjusting for sex, age, comorbidity, urbanization and facility level of care, the adjusted hazard ratio of overall psychiatric disorders for patients with vitiligo was 2.926 (95% confidence interval [CI], 2.646-3.236; P < 0.001). Among them, the highest adjusted hazard ratios were found for obsessive-compulsive disorder, at 10.790 (95% CI, 9.756-11.932; P < 0.001). Vitiligo is associated with an increased risk of various psychiatric disorders. By providing a better understanding of the psychosocial burden associated with vitiligo, these results emphasize the need to evaluate the mental health of patients with vitiligo by treating physicians.
© 2020 Japanese Dermatological Association.

Entities:  

Keywords:  anxiety; major depressive disorder; manic disorder; psychiatric disorders; vitiligo

Mesh:

Year:  2020        PMID: 32124495     DOI: 10.1111/1346-8138.15290

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  7 in total

1.  A deep learning-based hybrid artificial intelligence model for the detection and severity assessment of vitiligo lesions.

Authors:  Lifang Guo; Yin Yang; Hui Ding; Huiying Zheng; Hedan Yang; Junxiang Xie; Yong Li; Tong Lin; Yiping Ge
Journal:  Ann Transl Med       Date:  2022-05

2.  The Efficacy and Psychoneuroimmunology Mechanism of Camouflage Combined With Psychotherapy in Vitiligo Treatment.

Authors:  Yuqian Chang; Shaolong Zhang; Weigang Zhang; Shuli Li; Chunying Li
Journal:  Front Med (Lausanne)       Date:  2022-05-27

3.  Worsening Quality of Life in Young Adult, Highly Educated, and Married Female Patients with Vitiligo: A Hospital-Based Case Control Study in Taiwan.

Authors:  Yuan-Ting Yang; Chung-Hao Hsu; Yu-Fen Wang; Yu-Jun Chang; Hui-Ju Yang; Jiunn-Liang Ko; Kuo-Chia Yang
Journal:  Int J Environ Res Public Health       Date:  2022-05-31       Impact factor: 4.614

4.  [Screening for mental comorbidities in dermatology : Successful implementation of a screening for mental comorbidities in the field of inpatient dermatological treatment].

Authors:  Felix-Wilhelm Köster; Sebastian Kohlmann; Siobhan Loeper; Bernd Löwe; Stefan W Schneider
Journal:  Hautarzt       Date:  2021-03       Impact factor: 0.751

5.  Psychosocial Effects of Vitiligo: A Systematic Literature Review.

Authors:  Khaled Ezzedine; Viktoria Eleftheriadou; Heather Jones; Kristen Bibeau; Fiona I Kuo; Daniel Sturm; Amit G Pandya
Journal:  Am J Clin Dermatol       Date:  2021-09-23       Impact factor: 7.403

Review 6.  Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.

Authors:  Yinghan Wang; Shuli Li; Chunying Li
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-20       Impact factor: 8.667

7.  Meta-Analytic Review of High Anxiety Comorbidity among Patients with Vitiligo.

Authors:  Jiani Liu; Rui Tang; Yangfan Xiao; Mei Luo; Yaqian Shi; Qiancheng Deng; Huiming Zhang; Zhoutong Zeng; Zixin Pi; Rong Xiao
Journal:  Biomed Res Int       Date:  2021-05-17       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.